Menendez et al. ( 1 ) recently reported that γ -linolenic acid (GLA) suppresses the expression of the Her-2/neu (erbB-2) oncogene in several cancer cell lines in vitro and that concurrent treatments of Her-2 /neu -overexpressing cancer cells with GLA and the anti-Her-2/neu antibody showed synergistic increases in apoptosis and reduced growth and colony formation. These fi ndings are interesting but not surprising because it has previously been shown that several polyunsaturated fatty acids (PUFAs) -GLA, arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) -can kill a variety of tumor cells without harming normal cells, although the sensitivity of tumor cells to the cytotoxic action of these fatty acids varied ( 2 -4 ) .
In those studies, GLA was the most potent compound; the more highly unsaturated compounds AA, EPA, and DHA were also effective but were much less selective. This fi nding is surprising because it was thought that GLA and other fatty acids induce apoptosis of tumor cells by a free radical -dependent mechanism and so the higher the unsaturation index, the higher the tumoricidal ability [reviewed in (4) ]. In addition, GLA produced alterations in tumor cell membrane lipid composition and mitochondrial ultrastructure; induced a substantial decrease in the activity of mitochondrial respiratory chain complexes I + III, IV and mitochondrial membrane potential; increased cytochrome c release from mitochondria; and activated caspases and DNA fragmentation, leading to apoptosis of tumor cells [reviewed in ( 4 ) ]. GLA also decreased the antioxidant content of tumor cells, suppressed the expression of the oncogene Ras and the antiapoptotic gene Bcl-2, and enhanced the expression of p53 ( 5 ) . This action of GLA on gene expression could be related to the ability of its peroxidized products to bind to DNA ( 5 ) .
The ability of GLA to suppress the expression of the Her-2/neu (erbB-2) oncogene could be due to the binding of GLA and/or its peroxidized products to DNA. Her-2/neu (erbB-2) reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells by decreasing production of the free radical nitric oxide (NO) ( 6 ) . Further, the cyclooxygenase-2 (COX-2) product prostaglandin E 2 reverses the induction of apoptosis and NO production induced by the combination of N-(4-hydroxyphenyl)retinamide and COX-2 inhibitor in breast cancer cells ( 7 ) . This fi nding suggests that the Her-2/neu (erbB-2) oncogene behaves as an antioxidant and that the increased COX-2 activity seen in breast cancer cells is a protective mechanism developed by tumor cells to escape from the tumoricidal action of PUFAs. This observation implies that the activity of fatty acid-CoA ligase (FACL), another PUFA-utilizing enzyme, may be increased in drugresistant tumor cells. The relative resistance of cancer cells to apoptosis could be due to overexpression of COX-2 and FACL, which could serve as " sinks " for unesterifi ed PUFAs. If so, reduction of apoptosis could be inversely correlated with the cellular level of PUFAs. The apoptotic response of tumor cells that overexpress FACL and COX-2 could be restored by the addition of nonsteroidal anti-infl ammatory drugs and PUFAs. Thus, it is likely that one mechanism by which trastuzumab inhibits tumor growth is by enhancing free radical generation by blocking the Her-2/neu (erbB-2) oncogene. This mechanism could explain why a combination of GLA and trastuzumab led to synergistic increases in apoptosis.
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RESPONSE
We welcome the correspondence by Dr. Das on our recent report that the ω -6 fatty acid (FA) γ -linolenic acid (GLA; 18:3n-6) transcriptionally suppresses the Her-2/neu oncogene ( 1 ) . Although his molecular explanation for the synergism between GLA and trastuzumab is conceptually correct, it is unlikely that binding of GLA and/or its peroxidized products to DNA could explain this interaction.
Specifi cally, we do not agree with Das's suggestion that a general mechanism involving the generation of lipoperoxides probably explains Her-2/ neu suppression by GLA. Oleic acid (OA; 18:1n-9), the main ω -9 FA in olive oil, is monounsaturated whereas GLA is polyunsaturated. Nevertheless, OA is molecularly equivalent to GLA in that it suppresses Her-2/neu and interacts synergistically with trastuzumab ( 2 , 3 ) . Treatment with GLA or OA increases the expression of the transcriptional repressor PEA3 in Her-2/neu gene -amplifi ed tumor cells, and an intact PEA3 DNAbinding site on the endogenous Her-2/ neu promoter is essential for GLA-and OA-induced Her-2/neu repression. Thus, a PEA3 binding site -mutated sequence impairs GLA-or OA-induced transcriptional blockade of Her-2/neu, whereas this effect does not occur when a Simian virus 40 viral promoter controls Her-2/neu expression ( 1 , 3 ) . FAs other than GLA and OA can also modulate Her-2 / neu regardless of their saturation index, even in the presence of the antioxidant vitamin E ( 4 ) .
Because the effect is independent of the saturation index, lipoperoxide generation is unlikely to underlie it. Indeed, inhibition of fatty acid synthase (FAS) -catalyzed de novo biogenesis of saturated FA similarly suppresses Her-2/neu overexpression and interacts synergistically with trastuzumab by inducing PEA3 -dependent Her-2/neu repression ( 5 ) . We have recently found that specifi c depletion of FAS protein after transient transfection with a small inhibitory RNA that targets the FAS gene strongly antagonizes the anti-Her-2/neu effects of GLA (Menendez JA, Lupu R: unpublished data). That is, GLA-induced inhibition of Her-2/neu promoter activity cannot occur in the absence of FAS.
Considering the fact that GLA inhibits FAS effi ciently ( 6 ) , it is reasonable to suggest that FAS blockade is necessary and suffi cient to promote Her-2/neu repression. In agreement with this as sumption, bezafi brate, which blocks the activity of the rate-limiting enzyme of endogenous FA synthesis, acetyl-coenzyme A (CoA) carboxylase, did not reduce Her-2/neu promoter activity (Menendez JA, and Lupu RL: unpublished data). Conversely, the FAS sub strate malonyl-CoA on its own statistically signifi cantly decreased Her-2/neu promoter activity (Menendez JA, and Lupu R: unpublished data). Therefore, it appears that supraphysiological accumulation of malonyl-CoA, due to its reduced utilization by FAS in the presence of GLA, acts as an indicator of " cell fuel " availability that suppresses Her-2/neu via formation of inhibitory PEA3 protein -PEA3 DNA binding site complexes on the endogenous Her-2/neu promoter ( Fig.1 ) .
Finally, Das suggests that enhanced generation of free radicals could explain the synergism of GLA and trastuzumab because Her-2/neu directly participates in antioxidative processes. Our studies coincide with this suggestion but go further with the fi nding of Zhang et al. ( 7 ) that trastuzumab-sensitive proteins involved in metabolic and detoxifi cation pathways, including FAS, are highly expressed in Her-2/neu -positive breast cancer. In view of all these fi ndings, we consider Her-2/neu to be an " energy sensor " that actively participates in the response of cancer cells to non genotoxic metabolic stresses, thus opening a new molecular avenue in the management of Her-2/neu -overexpressing carcinomas. 
